Xeris Biopharma Holdings, Inc.
XERS
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodicā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$7.18
Price-1.10%
-$0.08
1Y
Price
Market Cap
$1.191b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+12.0%
EBITDA Margin-2.7%
Net Profit Margin+14.0%
Free Cash Flow MarginRevenue
$246.025m
+21.2%
1y CAGR+31.2%
3y CAGR+54.0%
5y CAGREarnings
-$31.999m
+41.7%
1y CAGR+29.3%
3y CAGR+27.7%
5y CAGREPS
-$0.22
+40.5%
1y CAGR+31.3%
3y CAGR+37.2%
5y CAGRBook Value
-$19.304m
$334.686m
Assets$353.990m
Liabilities$257.223m
DebtDebt to Assets
76.9%
34.8x
Debt to EBITDAFree Cash Flow
-$6.637m
+82.5%
1y CAGR+52.7%
3y CAGR+39.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company